Lipocalin-2: a novel potential therapy for GVHD.

IF 13.1 1区医学 Q1 IMMUNOLOGY

Trends in Immunology Pub Date : 2024-04-01 Epub Date: 2024-03-27 DOI:10.1016/j.it.2024.03.004

Kate A Markey

引用次数: 0

Abstract

Czech et al. used mouse models of allogeneic hematopoietic stem cell transplantation (allo-HCT) to investigate the role of lipocalin-2 (LCN2) as a newfound regulator of intestinal graft-versus-host disease (GVHD). Administration of recombinant LCN2 protein after disease onset prevented GVHD progression, suggesting that it may play a role in reversing tissue damage that has already begun.

查看原文本刊更多论文

脂质体蛋白-2：一种潜在的新疗法，可用于治疗风湿性关节炎。

捷克等人利用异体造血干细胞移植（allo-HCT）小鼠模型，研究脂钙蛋白-2（LCN2）作为肠道移植物抗宿主病（GVHD）新发现调节因子的作用。发病后服用重组LCN2蛋白可防止GVHD的发展，这表明它可能在逆转已经开始的组织损伤方面发挥作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in Immunology 医学-免疫学

CiteScore

25.10

自引率

0.60%

发文量

130

审稿时长

6-12 weeks

期刊介绍： Trends in Immunology serves as a vital platform for tracking advancements across various areas of immunology, offering concise reviews and hypothesis-driven viewpoints in each issue. With additional sections providing comprehensive coverage, the journal offers a holistic view of immunology. This broad perspective makes it an invaluable resource for researchers, educators, and students, facilitating the connection between basic and clinical immunology. Recognized as one of the top monthly review journals in its field, Trends in Immunology is highly regarded by the scientific community.